Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aktis Oncology, Inc. - Common stock (NQ:AKTS)

19.12 +0.09 (+0.47%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	147,602
Open	18.78
Bid (Size)	18.20 (100)
Ask (Size)	19.60 (100)
Prev. Close	19.03
Today's Range	18.36 - 19.22
52wk Range	14.72 - 29.16
Shares Outstanding	51,310,014
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Today 17:21 EDT

From Aktis Oncology Inc.

Via GlobeNewswire

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

Via The Motley Fool

Performance

YTD	-14.6%	-14.6%
1 Month	-6.7%	-6.7%
3 Month	+3.9%	+3.9%
6 Month	-14.6%	-14.6%
1 Year	-14.6%	-14.6%

More News

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

May 11, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology to Present at the BofA Securities Health Care Conference

May 06, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

May 04, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 21, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

April 16, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

March 30, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology to Present at Upcoming March Investor Conferences

February 24, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

February 24, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

Via MarketMinute

MarketBeat Week in Review – 01/12 - 01/16 ↗

January 17, 2026

Via MarketBeat

A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗

January 14, 2026

Via MarketBeat

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 13, 2026

From Aktis Oncology Inc.

Via GlobeNewswire

12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗

December 16, 2024

Via Benzinga

Crude Oil Down 1%; Webuy Global Shares Spike Higher ↗

December 16, 2024

Via Benzinga

Nasdaq Surges Over 100 Points; NY Empire State Manufacturing Index Dips In December ↗

December 16, 2024

Via Benzinga

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗

December 16, 2024

Via Benzinga

Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

December 16, 2024

From Akoustis, Inc.

Via GlobeNewswire

Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

December 16, 2024

From Akoustis, Inc.

Via Business Wire

12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

November 25, 2024

Via Benzinga

12 Information Technology Stocks Moving In Friday's Pre-Market Session ↗

November 22, 2024

Via Benzinga

12 Information Technology Stocks Moving In Thursday's Pre-Market Session ↗

November 21, 2024

Via Benzinga

12 Information Technology Stocks Moving In Monday's After-Market Session ↗

October 28, 2024

Via Benzinga

Frequently Asked Questions

Is Aktis Oncology, Inc. - Common stock publicly traded?

Yes, Aktis Oncology, Inc. - Common stock is publicly traded.

What exchange does Aktis Oncology, Inc. - Common stock trade on?

Aktis Oncology, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aktis Oncology, Inc. - Common stock?

The ticker symbol for Aktis Oncology, Inc. - Common stock is AKTS on the Nasdaq Stock Market

What is the current price of Aktis Oncology, Inc. - Common stock?

The current price of Aktis Oncology, Inc. - Common stock is 19.12

When was Aktis Oncology, Inc. - Common stock last traded?

The last trade of Aktis Oncology, Inc. - Common stock was at 05/21/26 04:00 PM ET

What is the market capitalization of Aktis Oncology, Inc. - Common stock?

The market capitalization of Aktis Oncology, Inc. - Common stock is 981.05M

How many shares of Aktis Oncology, Inc. - Common stock are outstanding?

Aktis Oncology, Inc. - Common stock has 981M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.